Application of RGD tripeptides in preparation of medicines for treating Alzheimer disease

The invention discloses application of RGD tripeptides in preparation of medicines for preventing or treating Alzheimer disease, belonging to the field of medicines. The RGD tripeptide disclosed by the invention is clear in dosage, can be prepared into tablets, microspheres, powder, oral liquid and injection and can be in single medication and be combined with other Alzheimer disease medicines of different mechanisms of action in the treatment of Alzheimer disease, and a pharmaceutical composition consisting of the RGD tripeptide, tetrandrine and triptolide is used for treating the Alzheimer disease, so that the toxic and side effects of the medicines can be reduced, and a collaborative treatment effect can be achieved. The pharmacological experiment proves that the RGD tripeptide can effectively inhibit Abeta1-42 aggregation and preventing oligomerization of Abeta1-42 monomers, obviously inhibits deposition of beta amyloid proteins, is exact in curative effect of preventing or treating the Alzheimer disease and has small side effects. Therefore, the RGD tripeptide has wide medical application prospects.